Biophytis

Biophytis PP&E per Employee

The PP&E per Employee of Biophytis (ALBPS.PA) as of Oct 30, 2026 is 10,500.00 EUR. In the previous year, PP&E per Employee was 14,318.18 EUR — a change of -26.67% (lower).

PP&E per Employee

10,500.00EUR

YoY

-26.67%

Last updated:

PP&E per Employee of Biophytis is 2024 10,500.00 EUR. PP&E per Employee of Biophytis was 2023 14,318.18 EUR. It decreases by -26.67% lower compared to the previous year.

The Biophytis PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2017
14,227.27 EUR
Jan 1, 2018
13,409.09 EUR
Jan 1, 2019
8,409.09 EUR
Jan 1, 2020
5,181.82 EUR
Jan 1, 2021
25,590.91 EUR
Jan 1, 2022
26,545.45 EUR
Jan 1, 2023
14,318.18 EUR
Jan 1, 2024
10,500.00 EUR
The Biophytis PP&E per Employee history
YEARPP&E per EmployeeYoY
10,500.00EUR-26.67%
14,318.18EUR-46.06%
26,545.45EUR+3.73%
25,590.91EUR+393.86%
5,181.82EUR-38.38%
8,409.09EUR-37.29%
13,409.09EUR-5.75%
14,227.27EUR+13.41%
12,545.45EUR+42.27%
8,818.18EUR+870.00%
909.09EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

PP&E per Employee of Biophytis is 10,500.00 EUR in 2024.

PP&E per Employee of Biophytis changed from 14,318.18 EUR to 10,500.00 EUR, representing a -26.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Biophytis since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Biophytis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biophytis

All Key Metrics — Biophytis